Enhanced protective efficacy of H5 subtype influenza vaccine with modification of the multibasic cleavage site of hemagglutinin in retroviral pseudotypes

Virologica Sinica

Volumn 28, Issue 3, 2013, Pages 136-145

  Tao, Ling ^a,b   Chen, Jianjun ^a   Meng, Jin ^a   Chen, Yao ^a   Li, Hongxia ^a   Liu, Yan ^a   Zheng, Zhenhua ^a   Wang, Hanzhong ^a  

^a WUHAN INSTITUTE OF VIROLOGY   (China)

^b CHONGQING ACADEMY OF CHINESE MATERIA MEDICA   (China)

Author keywords

H5 subtype; Hemagglutinin; Influenza; Multibasic cleavage site; Pseudotype; Vaccine

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G; INFLUENZA VACCINE; VIRUS HEMAGGLUTININ; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNIZATION; INFECTION PREVENTION; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; INOCULATION; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION;

ANIMALS; ANTIBODIES, VIRAL; GENETIC VECTORS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA VACCINES; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MICE; MUTANT PROTEINS; RECOMBINANT PROTEINS; RETROVIRIDAE; VACCINES, SYNTHETIC;

AVIAN INFLUENZA VIRUS; MAMMALIA; MUS; ORTHOMYXOVIRIDAE;

EID: 84879240505     PISSN: 16740769     EISSN: 1995820X     Source Type: Journal    
DOI: 10.1007/s12250-013-3326-5     Document Type: Article

References (51)

1. Ao Z, Patel A, Tran K, He X, Fowke K, Coombs K, Kobasa D, Kobinger G, and Yao X. 2008. Characterization of a trypsin-dependent avian influenza H5N1-pseudotyped HIV vector system for high throughput screening of inhibitory molecules. Antiviral Res, 79: 12-18.
2. Braciale T J, Morrison L A, Sweetser M T, Sambrook J, Gething M J, and Braciale V L. 1987. Antigen presentation pathways to class I and class II MHC-restricted T lymphocytes. Immunol. Rev., 98: 95-114.
3. Bresson J L, Perronne C, Launay O, Gerdil C, Saville M, Wood J, Hoschler K, and Zambon M C. 2006. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet, 367: 1657-1664.
4. Chen J, Lee K H, Steinhauer D A, Stevens D J, Skehel J J, and Wiley D C. 1998. Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation. Cell, 95: 409-417.
5. Claas E C, Osterhaus A D, van Beek R, De Jong J C, Rimmelzwaan G F, Senne D A, Krauss S, Shortridge K F, and Webster R G. 1998. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet, 351: 472-477.
6. Ehrlich H J, Muller M, Oh H M, Tambyah P A, Joukhadar C, Montomoli E, Fisher D, Berezuk G, Fritsch S, Low-Baselli A, Vartian N, Bobrovsky R, Pavlova B G, Pollabauer E M, Kistner O, and Barrett P N. 2008. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med, 358: 2573-2584.
7. Garcia J M, Lagarde N, Ma E S, de Jong M D, and Peiris J S. 2010. Optimization and evaluation of an influenza A (H5) pseudotyped lentiviral particle-based serological assay. J. Clin. Virol., 47: 29-33.
8. Giroglou T, Cinatl J, Rabenau H, Drosten C, Schwalbe H, Doerr H W, and von Laer D. 2004. Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein. J. Virol., 78: 9007-9015.
9. Haynes J R, Dokken L, Wiley J A, Cawthon A G, Bigger J, Harmsen A G, and Richardson C. 2009. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. Vaccine, 27: 530-541.
10. Herfst S, Schrauwen E J, Linster M, Chutinimitkul S, de Wit E, Munster V J, Sorrell E M, Bestebroer T M, Burke D F, Smith D J, Rimmelzwaan G F, Osterhaus A D, and Fouchier R A. 2012. Airborne transmission of influenza A/H5N1 virus between ferrets. Science, 336: 1534-1541.
11. Ho J W, Hershkovitz O, Peiris M, Zilka A, Bar-Ilan A, Nal B, Chu K, Kudelko M, Kam Y W, Achdout H, Mandelboim M, Altmeyer R, Mandelboim O, Bruzzone R, and Porgador A. 2008. H5-type influenza virus hemagglutinin is functionally recognized by the natural killer-activating receptor NKp44. J. Virol., 82: 2028-2032.
12. Horimoto T, and Kawaoka Y. 1994. Reverse genetics provides direct evidence for a correlation of hemagglutinin cleavability and virulence of an avian influenza A virus. J. Virol., 68: 3120-3128.
13. Horimoto T, Nakayama K, Smeekens S P, and Kawaoka Y. 1994. Proprotein-processing endoproteases PC6 and furin both activate hemagglutinin of virulent avian influenza viruses. J. Virol., 68: 6074-6078.
14. Howard M K, Kistner O, and Barrett P N. 2008. Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines. Biological Chemistry, 389: 569-577.
15. Imai M, Watanabe T, Hatta M, Das S C, Ozawa M, Shinya K, Zhong G, Hanson A, Katsura H, Watanabe S, Li C, Kawakami E, Yamada S, Kiso M, Suzuki Y, Maher E A, Neumann G, and Kawaoka Y. 2012. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature, 486: 420-428.
16. Kistner O, Howard M K, Spruth M, Wodal W, Bruhl P, Gerencer M, Crowe B A, Savidis-Dacho H, Livey I, Reiter M, Mayerhofer I, Tauer C, Grillberger L, Mundt W, Falkner F G, and Barrett P N. 2007. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine, 25: 6028-6036.
17. Kong W P, Hood C, Yang Z Y, Wei C J, Xu L, Garcia-Sastre A, Tumpey T M, and Nabel G J. 2006. Protective immunity to lethal challenge of the 1918 pandemic influenza virus by vaccination. Proc. Natl. Acad. Sci. U.S.A., 103: 15987-15991.
18. Li S, Liu C, Klimov A, Subbarao K, Perdue M L, Mo D, Ji Y, Woods L, Hietala S, and Bryant M. 1999. Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses. J. Infect. Dis., 179: 1132-1138.
19. Lin A H, and Cannon P M. 2002. Use of pseudotyped retroviral vectors to analyze the receptor-binding pocket of hemagglutinin from a pathogenic avian influenza A virus (H7 subtype). Virus Res., 83: 43-56.
20. Lin J, Zhang J, Dong X, Fang H, Chen J, Su N, Gao Q, Zhang Z, Liu Y, Wang Z, Yang M, Sun R, Li C, Lin S, Ji M, Wang X, Wood J, Feng Z, Wang Y, and Yin W. 2006. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet, 368: 991-997.
21. Lu B, Tao L, Wang T, Zheng Z, Li B, Chen Z, Huang Y, Hu Q, and Wang H. 2009. Humoral and cellular immune responses induced by 3a DNA vaccines against severe acute respiratory syndrome (SARS) or SARS-like coronavirus in mice. Clin. Vaccine Immunol., 16: 73-77.
22. Lu X, Tumpey T M, Morken T, Zaki S R, Cox N J, and Katz J M. 1999. A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. J Virol, 73: 5903-5911.
23. Nefkens I, Garcia J M, Ling C S, Lagarde N, Nicholls J, Tang D J, Peiris M, Buchy P, and Altmeyer R. 2007. Hemagglutinin pseudotyped lentiviral particles: characterization of a new method for avian H5N1 influenza sero-diagnosis. J. Clin. Virol., 39: 27-33.
24. Okumura Y, Takahashi E, Yano M, Ohuchi M, Daidoji T, Nakaya T, Bottcher E, Garten W, Klenk H D, and Kido H. 2010. Novel type II transmembrane serine proteases, MSPL and TMPRSS13, Proteolytically activate membrane fusion activity of the hemagglutinin of highly pathogenic avian influenza viruses and induce their multicycle replication. J. Virol., 84: 5089-5096.
25. Schrauwen E J, Herfst S, Leijten L M, van Run P, Bestebroer T M, Linster M, Bodewes R, Kreijtz J H, Rimmelzwaan G F, Osterhaus A D, Fouchier R A, Kuiken T, and van Riel D. 2012. The multibasic cleavage site in H5N1 virus is critical for systemic spread along the olfactory and hematogenous routes in ferrets. J Virol, 86: 3975-3984.
26. Senne D A, Panigrahy B, Kawaoka Y, Pearson J E, Suss J, Lipkind M, Kida H, and Webster R G. 1996. Survey of the hemagglutinin (HA) cleavage site sequence of H5 and H7 avian influenza viruses: amino acid sequence at the HA cleavage site as a marker of pathogenicity potential. Avian Dis, 40: 425-437.
27. Skehel J J, and Wiley D C. 2000. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem, 69: 531-569.
28. Song J M, Hossain J, Yoo D G, Lipatov A S, Davis C T, Quan F S, Chen L M, Hogan R J, Donis R O, Compans R W, and Kang S M. 2010. Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology, 405: 165-175.
29. Stech J, Garn H, Wegmann M, Wagner R, and Klenk H D. 2005. A new approach to an influenza live vaccine: modification of the cleavage site of hemagglutinin. Nat Med, 11: 683-689.
30. Steinhauer D A. 1999. Role of hemagglutinin cleavage for the pathogenicity of influenza virus. Virology, 258: 1-20.
31. Stieneke-Grober A, Vey M, Angliker H, Shaw E, Thomas G, Roberts C, Klenk H D, and Garten W. 1992. Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease. EMBO J., 11: 2407-2414.
32. Subbarao K, Chen H, Swayne D, Mingay L, Fodor E, Brownlee G, Xu X, Lu X, Katz J, Cox N, and Matsuoka Y. 2003. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology, 305: 192-200.
33. Subbarao K, Klimov A, Katz J, Regnery H, Lim W, Hall H, Perdue M, Swayne D, Bender C, Huang J, Hemphill M, Rowe T, Shaw M, Xu X, Fukuda K, and Cox N. 1998. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science, 279: 393-396.
34. Suguitan A L, Marino M P, Desai P D, Chen L M, Matsuoka Y, Donis R O, Jin H, Swayne D E, Kemble G, and Subbarao K. 2009. The influence of the multi-basic cleavage site of the H5 hemagglutinin on the attenuation, immunogenicity and efficacy of a live attenuated influenza A H5N1 cold-adapted vaccine virus. Virology, 395: 280-288.
35. Suguitan A L, Jr., Matsuoka Y, Lau Y F, Santos C P, Vogel L, Cheng L I, Orandle M, and Subbarao K. 2012. The multibasic cleavage site of the hemagglutinin of highly pathogenic A/Vietnam/1203/2004 (H5N1) avian influenza virus acts as a virulence factor in a host-specific manner in mammals. J Virol, 86: 2706-2714.
36. Szecsi J, Boson B, Johnsson P, Dupeyrot-Lacas P, Matrosovich M, Klenk H D, Klatzmann D, Volchkov V, and Cosset F L. 2006. Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses. Virol. J., 3: 70.
37. Tambyah P A, Wilder-Smith A, Pavlova B G, Barrett P N, Oh H M, Hui D S, Yuen K Y, Fritsch S, Aichinger G, Loew-Baselli A, van der Velden M, Maritsch F, Kistner O, and Ehrlich H J. 2012. Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine. Vaccine, 30: 329-335.
38. Tao L, Chen J, Zheng Z, Meng J, Zhang Z, Chen Y, Luo H, Li H, Chen Z, Hu Q, and Wang H. 2012. H5N1 influenza virus-like particles produced by transient expression in mammalian cells induce humoral and cellular immune responses in mice. Can J Microbiol, 58: 391-401.
39. Temperton N J, Hoschler K, Major D, Nicolson C, Manvell R, Hien V M, Ha do Q, de Jong M, Zambon M, Takeuchi Y, and Weiss R A. 2007. A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies. Influenza Other Respi Viruses, 1: 105-112.
40. Tsai C G, Caillet C, Hu H X, Zhou F, Ding H, Zhang G L, Zhou B P, Wang S X, Lu S, Buchy P, Deubel V, Vogel F R, and Zhou P. 2009. Measurement of neutralizing antibody responses against H5N1 clades in immunized mice and ferrets using pseudotypes expressing influenza hemagglutinin and neuraminidase. Vaccine, 27: 6777-6790.
41. Wang S Y, Su C Y, Lin M, Huang S Y, Huang W I, Wang C C, Wu Y T, Cheng T J, Yu H M, Ren C T, Wu C Y, Wong C H, and Cheng Y S. 2009. HA-pseudotyped retroviral vectors for influenza antagonist screening. J Biomol Screen, 14: 294-302.
42. Wang S Y, Su C Y, Lin M G, Huang S Y, Huang W I, Wang C C, Wu Y T, Cheng T J R, Yu H M, Ren C T, Wu C Y, Wong C H, and Cheng Y S E. 2009. HA-Pseudotyped Retroviral Vectors for Influenza Antagonist Screening. J. Biomol. Screen., 14: 294-302.
43. Wang W, Xie H, Ye Z, Vassell R, and Weiss C D. 2010. Characterization of lentiviral pseudotypes with influenza H5N1 hemagglutinin and their performance in neutralization assays. J. Virol. Methods, 165: 305-310.
44. Wang W, Butler E N, Veguilla V, Vassell R, Thomas J T, Moos M, Ye Z P, Hancock K, and Weiss C D. 2008. Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies. J. Virol. Methods, 153: 111-119.
45. Webby R J, Perez D R, Coleman J S, Guan Y, Knight J H, Govorkova E A, McClain-Moss L R, Peiris J S, Rehg J E, Tuomanen E I, and Webster R G. 2004. Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet, 363: 1099-1103.
46. WHO. 2013. Cumulative number of confirmed human cases for avian influenza A (H5N1) reported to WHO, 2003-2013.
47. Wu C Y, Yeh Y C, Yang Y C, Chou C, Liu M T, Wu H S, Chan J T, and Hsiao P W. 2010. Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus. PLoS One, 5: e9784.
48. Wu Q, Fang L, Wu X, Li B, Luo R, Yu Z, Jin M, Chen H, and Xiao S. 2009. A pseudotype baculovirus-mediated vaccine confers protective immunity against lethal challenge with H5N1 avian influenza virus in mice and chickens. Mol. Immunol., 46: 2210-2217.
49. Yin J, Liu S, and Zhu Y. 2013. An overview of the highly pathogenic H5N1 influenza virus. Virol Sin, 28: 3-15.
50. Zhang S, Xiao L, Zhou H, Yu Z, Chen H, Guo A, and Jin M. 2008. Generation and characterization of an H5N1 avian influenza virus hemagglutinin glycoprotein pseudotyped lentivirus. J. Virol. Methods, 154: 99-103.
51. Zheng L, Wang F, Yang Z, Chen J, Chang H, and Chen Z. 2009. A single immunization with HA DNA vaccine by electroporation induces early protection against H5N1 avian influenza virus challenge in mice. BMC Infect. Dis., 9: 17.